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Quality of surgical care can impact
survival in patients with bladder cancer
after robot‑assisted radical cystectomy: results
from the International Robotic Cystectomy
Consortium
Youssef Ahmed1, Ahmed A. Hussein1,2*, Paul R. May1, Basel Ahmad1, Amir Khan1, John Benkowski1,
Ayesha Durrani1, Saira Khan1, Justen Kozlowski1, Matthias Saar3, Carl J. Wijburg4, Lee Richstone5,
Andrew Wagner6, Bertram Yuh7, Joan Palou Redorta8, Prokar Dasgupta9, Mohammad Shamim Khan9,
Mani Menon10, James O. Peabody10, Abolfazl Hosseini11, Franco Gaboardi12, Giovannalberto Pini12,
Francis Schanne13, Alexandre Mottrie14, Koon‑ho Rha15, Ashok Hemal16, Michael Stockle3, John Kelly17,
Wei Shen Tan17, Thomas J. Maatman18, Vassilis Poulakis19, Jihad Kaouk20, Abdullah Erdem Canda21,
Mevlana Derya Balbay21, Peter Wiklund11 and Khurshid A. Guru1*

Abstract
Background: Although pathological factors remain the main determinate of survival for patients with bladder
cancer, quality of surgical care is crucial for satisfactory outcomes. Using a validated quality score, we investigated the
impact of surgical factors on the overall survival (OS), recurrence-free survival (RFS) and disease-specific survival (DSS)
in patients with locally advanced and organ-confined disease (OCD). Retrospective review of IRCC database includes
2460 patients from 29 institutions across 11 countries. The final cohort included 1343 patients who underwent RARCs
between 2005 and 2016. Patients with locally advanced disease (LAD) (> pT2 and/or N +) were compared with OCD
(≤ pT2/N0). Validated Quality Cystectomy Score (QCS) based on four sets of quality metrics was used to compare sur‑
gical performance. Kaplan–Meier method was used to compute RFS, CSS and OS rates. Multivariable stepwise logistic
regression was used to evaluate variables associated with RFS, DSS and OS.
Results: 48% had LAD. When compared to patients with OCD, they received neobladders less frequently (17% vs.
28%, p < 0.001) and experienced higher estimated blood loss (513 vs. 376 ml, p = 0.05). Postoperatively, more patients
in the LAD group received adjuvant chemotherapy (24% vs. 4%, p < 0.001) and positive surgical margins (14% vs. 2%,
p < 0.001) and had higher 90-day mortality (6% vs. 2%, p < 0.001). On multivariable analysis, female gender, higher QCS
score, intracorporeal diversion, pT stage, positive lymph node status and recurrence are considered as predictors of
survival. Patients with OCD exhibited better RFS, DSS and OS than patients with LAD. For patients with OCD, higher
QCS was associated with improved OS but not RFS or DSS. On the other hand, patients with LAD and higher QCS
exhibited higher RFS, DSS and OS when compared to those with lower QCS.

*Correspondence: ahmedalyhussein@kasralainy.edu.eg; khurshid.
guru@roswellpark.org
1
Roswell Park Cancer Institute, Elm & Carlton St, Buffalo, NY 14263, USA
Full list of author information is available at the end of the article
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeco
mmons.org/licenses/by/4.0/.

Ahmed et al. Afr J Urol

(2020) 26:22

Page 2 of 8

Conclusion: Quality of surgical care can affect disease control and OS in patients with bladder cancer treated with
robot-assisted radical cystectomy.
Keywords: Bladder cancer, Robotic, Cystectomy, Locally advanced, Organ confined, Quality

1 Background
Robot-assisted radical cystectomy (RARC) has been
increasingly utilized for muscle-invasive bladder cancer,
as it provides similar oncological efficacy to open radical cystectomy (RC) and is superior in terms of perioperative outcomes and recovery [1]. Approximately 37% of
patients have locally advanced disease (LAD) (extravesical disease (> pT2) and/or positive lymph nodes) at surgery [2]. The negative impact of tumor stage (pT stage)
and lymph node stage (pN stage) on oncological outcomes following RC has been reported by several open
and robot-assisted series [3–5]. Surgery in the setting
of LAD may invariably become inevitable to alleviate
adverse urinary symptoms and poor quality of life that
may occur [6]. Additionally, similar to ovarian cancer and
renal cell carcinoma, surgery offers good local control,
decreases tumor burden and therefore may be associated
with survival benefit [7]. Moreover, advents in neoadjuvant chemotherapy (NAC) have been associated with significant pathologic downstaging and improved survival,
and surgery may be done even with curative intent in this
setting [8].
Controversy remains with regards to the best approach
for locally advanced bladder cancer, with concerns
regarding poor oncological outcomes, higher morbidity and mortality, cost-effectiveness and the economic
impact [9]. In addition to patient comorbidities and
extent of the disease, it has been shown that quality of
surgical performance can largely contribute to outcomes
of RC independent of the extent of the disease [10, 11].
However, the role RARC in the setting of LAD is yet to
be defined. The lack of tactile feedback and the potential higher risk of positive surgical margins may advocate against the use of RARC [12]. Additionally, there
have been concerns about possible higher incidence of
extrapelvic lymph node (LN) metastasis, local recurrence
and peritoneal carcinomatosis with RARC when compared to open surgery [13].
In this context, we sought to describe the outcomes of
our patients who underwent RARC for LAD and investigate the impact of quality of surgical performance on
perioperative outcomes and survival.
2 Methods
A retrospective review of the International Robotic Cystectomy Consortium (IRCC) database was performed
(I-79606) which includes 2460 patients who underwent

RARC between 2005 and 2016, from 29 institutions
across 11 countries.
Patients were divided into two groups: patients with
LAD (> pT2 and/or N +) and those with organ-confined
disease (OCD) (≤ pT2/N0). Patients were reviewed for
demographics (age, sex, body mass index [BMI] and
American Society of Anesthesiologists [ASA] score), preoperative characteristics (prior abdominal or pelvic surgery, prior irradiation, neoadjuvant chemotherapy [NAC]
and clinical staging), operative (type and technique of
diversion, operative time, blood loss and transfusion),
postoperative variables (hospital and intensive care unit
stay, complications, readmissions, pathological staging,
lymph node yield) and oncological outcomes (disease
recurrence and survival). Patients were again grouped
according to the quality of surgical care they received,
measured by the validated Quality Cystectomy Score
(QCS) for RARC into high and low QCS [10]. The score
comprises four domains that measure surgical quality of
RARC independent of patient and disease characteristics
and then assigned a star score depending on the number of quality metrics fulfilled (Additional file 1: Fig. S1).
Oncological outcomes were then compared between the
different groups.
2.1 Statistical analysis

Data were described in terms of means and standard
deviations. Univariable associations were statistically
assessed using the Wilcoxon rank sum test or Kruskal–
Wallis test for ordinal data, and Pearson chi-square test
for categorical variables. Kaplan–Meier curves were
used to describe recurrence-free (RFS), disease-specific
(DSS) and overall (OS) survival. Multivariable stepwise
logistic regression models were fit to evaluate preoperative, operative and postoperative predictors of RFS, DSS
and OS, excluding factors included in the QCS to avoid
collinearity. All tests were two-sided, with statistical significance defined as p < 0.05. All statistical analyses were
performed using SAS software (version 9.3, SAS Institute
Inc., Cary, NC).

3 Results
The final cohort comprised 1343 patients, 41 surgeons
from 24 institutions in 10 countries. Mean age was
67 years, 74% were men and 20% received NAC. A total
of 640 (48%) patients had LAD (86% had extravesical
disease, 47% had positive lymph nodes and 33% had
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both). Patients with LAD received ileal conduits more
often (83% vs. 72%, p < 0.001), experienced higher estimated blood loss (444 vs. 376 ml, p = 0.05) and received
adjuvant chemotherapy more often (24% vs. 4%,
p < 0.001). Both groups exhibited a similar lymph node
yield (median 18, standard deviation [SD] 11). There
was no significant difference in terms of operative

times, complications or readmissions up to 3 months
after RARC. LAD patients had more positive soft tissue surgical margins (14% vs. 2%, p < 0.001). They had
higher incidence of both local (19% vs. 4%, p < 0.001)
and distant (31% vs. 8%, p < 0.001) recurrences. They
also exhibited higher mortality at 90 days (6% vs. 2%,
p < 0.001) (Table 1).

Table 1 Perioperative characteristics of patients who underwent RARC between 2005 and 2016 (OC vs. LAD)
Variable

OCD

LAD

p value

N (%)

703 (52)

640 (48)

–

Preoperative
Age, mean (SD), years
Sex, males, n (%)
BMI, kg/m2, mean (SD)
ASA score, median (IQR)

67 (10)

68 (10)

0.04

528 (75)

461 (72)

0.24

28 (5)

27 (5)

0.01

2 (2–3)

3 (2–3)

0.06

Prior surgery, n (%)

221 (31)

209 (33)

0.63

NAC, n (%)

139 (20)

126 (20)

0.97

Ileal conduit, n (%)

503 (72)

529 (83)

< 0.001

Intracorporeal diversion, n (%)

435 (76)

347 (72)

0.12

Operative time, median (IQR), min

371 (310–450)

369 (310–442)

0.80

EBL, mean (SD), ml

376 (339)

444 (513)

0.05

Operative

Perioperative
Hospital stay, median (IQR), days

9 (7–13)

9 (7–13)

0.42

ICU stay, median (IQR), days

1 (0–1)

1 (0–1)

0.73

26 (4)

154 (24)

< 0.001

30-d complications, n (%)

Adjuvant treatment, n (%)

224 (32)

205 (32)

0.95

90-d complications, n (%)

261 (37)

249 (39)

0.50

30-d high-grade complications, n (%)

63 (9)

72 (11)

0.16

90-d high-grade complications, n (%)

74 (11)

88 (14)

0.07

30-d readmission, n (%)

48 (7)

50 (8)

0.49

90-d readmission, n (%)

85 (12)

91 (14)

0.25

30-d mortality, n (%)
90-d mortality, n (%)

4 (0.6)

7 (1)

12 (1.9)

33 (6)

< 0.001

0.29

Pathologic
18 (11)

18 (11)

0.86

Positive LN, n (%)

LNY, mean (SD)

0 (0)

301 (47)

NA

Pathologic T stage > 2

0 (0)

544 (86)

16 (2)

89 (14)

PSM, n (%)

NA
< 0.001

Any recurrence, n (%)

73 (10)

252 (39)

< 0.001

Local recurrence, n (%)

31 (4)

123 (19)

< 0.001

Distant recurrence (n)

56 (8)

198 (31)

Median time to any recurrence (months)

12 (6-21)

Non-TCC histology, n (%)

6 (3-11)

< 0.001
< 0.001

163 (30)

171 (30)

0.76

Preoperative

139 (20)

126 (20)

0.97

Operative

359 (51)

318 (50)

0.61

Postoperative

603 (86)

529 (83)

0.12

266 (38)

209 (33)

0.05

QCS domains

Pathologic
Bold indicates statistically significant difference
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In terms of quality of surgical care provided, both
groups received comparable surgical care, where 83%
of LAD patients were assigned a high QCS score (3–4
stars) compared to 90% of OCD patients (Fig. 1). The
proportion of patients who received high QCS score significantly increased with time, irrespective of their disease extent (linear regression test: OCD: p = 0.003; LAD
p = 0.02) (Fig. 2).
Patients with high QCS significantly demonstrated better 5-year OS irrespective of their disease stage (LAD:
29% vs. 23%, p = 0.02) and (OCD: 70% vs. 55%, p = 0.03).
When compared to patients who had LAD and low QCS,
patients with LAD and high QCS demonstrated better
5-year RFS (41% vs. 29%, p = 0.05) and DSS (55% vs. 37%,
p = 0.01). This benefit was not demonstrated for patients
with OCD (Fig. 3).
Looking at predictors of survival, > pT3 stage and N+
status at RARC were associated with worse RFS (hazards
ratio [HR] 1.60, 95% confidence interval [CI] 1.15–2.22,
p = 0.006; HR 1.63, 95% CI 1.19–2.24, p = 0.003), DSS
(HR 5.12, 95% CI 3.23–8.12, p < 0.0001; HR 2.05, 95% CI
1.39–3.04, p = 0.0003) and OS (HR 3.66, 95% CI 2.76–
4.84, p < 0.0001; HR 1.83, 95% CI 1.4–2.40, p < 0.0001),
respectively. Patients who received neobladders and high
QCS score exhibited better DSS (HR 0.30, 95% CI 0.12–
0.74, p = 0.009; HR 0.53, 95% CI 0.34–0.84, p = 0.007) and
OS (HR 0.366, 95% CI 0.21–0.65, p = 0.0005; HR 0.63,
95% CI 0.46–0.86, p = 0.004). BMI had a modest effect on
DSS and OS. Male patients (HR 0.69, 95% CI 0.49–0.95,
p = 0.02) and those who received extracorporeal diversion (HR 0.67, 95% CI 0.49–0.91, p = 0.01) demonstrated
better RFS. Higher ASA score was associated with worse
OS (HR 1.41, 95% CI 1.13–1.75, p = 0.002) (Table 2).

24%

Fig. 2 Proportion of patients who received high QCS (star score of 3
or 4) over time (linear regression test: OCD, p = 0.003 vs. LAD, p = 0.02)

4 Discussion
For decades, RC has been the gold standard for treatment
of muscle-invasive bladder cancer and refractory nonmuscle-invasive disease. However, even with the advents
in surgical techniques and perioperative care, it remains
with considerable morbidity and mortality, especially
for LAD (pT3–T4 and/or lymph node-positive) [14]. We
aimed to explore the outcomes of RARC in the setting of
locally advanced bladder cancer and whether the quality of surgical care affected survival in this setting or not
(Additional file 2: Table S1).
Although RC in LAD (alone or as part of multimodality approach) may be of considerable risks, other alternatives, as bladder preservation modalities, which usually
entail radiation and chemotherapy combined with transurethral resection (TUR) of the primary tumor, do not

OCD

LAD

0%

1%
11%
1 Star
2 Star
3 Star
4 Star

17%

23%

65%
Fig. 1 Pie chart showing the distribution of QCS scores among patients with LAD versus OCD

59%

1 Star
2 Star
3 Star
4 Star
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a- RFS:
LAD High QCS
LAD Low QCS
OCD High QCS
OCD Low QCS

RFS High vs Low QCS (LAD p=0.046, OCD p=0.40)

b- DSS:

DSS High vs Low QCS (LAD p=0.01, OCD p=0.90)

c- OS:

OS High vs Low QCS (LAD p=0.02, OCD p=0.03)

Fig. 3 Kaplan–Meier curves for RFS, DSS and OS for patients with OCD versus LAD stratified by QCS score (high QCS vs. low QCS)
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Table 2 Multivariable stepwise Cox proportional hazards regression modeling predictors of RFS, DSS and OS
Variables

Gender (females)

RFS

DSS

HR

CI

p

0.685

0.493–0.952

0.02

BMI

OS

HR

CI

0.956

0.924–0.99

p

HR

0.01

ASA
Diversion type (ileal conduit)
Diversion approach (intracorporeal)

0.297
0.67

0.49–0.91

0.12–0.736

0.009

CI

p

0.964

0.943–0.986

0.002

1.409

1.133–1.751

0.002

0.366

0.208–0.645

0.0005

0.01

pT (≤ pT2)

1.595

1.146–2.218

0.006

5.119

3.225–8.124

<0.0001

3.656

2.762–4.837

< 0.0001

pN (N–)

1.629

1.185–2.239

0.003

2.053

1.385–3.043

0.0003

1.833

1.4–2.399

< 0.0001

0.533

0.338–0.84

0.007

0.629

0.457–0.864

QCS (low QCS)

provide adequate primary tumor control. Additionally,
they may be associated with worse voiding symptoms,
uncontrollable bleeding, repeated hospital readmissions
and poor quality of life [15]. Inadequate local tumor
control may also cause fistulation, ureteral obstruction
and symptomatic distant metastasis [6]. Consequently,
approximately one-quarter of the patients will undergo
salvage cystectomy for symptom relief [16]. RC following
extensive chemo-irradiation and multiple TURs has very
limited clinical efficacy and usually associated with even
higher morbidity and mortality [17]. Therefore, resection of the bladder with an adequate safety margin and
extended lymph node dissection may offer symptomatic
relief and offer some oncological benefits especially when
combined with chemotherapy for control of micrometastatic disease [6].
The present outcomes showed similar perioperative
outcomes between LAD and OCD, with only modest difference in the estimated blood loss (444 vs. 376). More
patients in the LAD showed PSM (14% vs. 2%, p < 0.001)
and experienced recurrence more often (39% vs. 10%,
p < 0.001). This can be explained by disease aggressiveness. Even with adequate surgical techniques, LAD
cohort may still experience more positive soft tissue surgical margins, which is associated with disease relapse
[18, 19].
Survival following RARC depends on several key factors: stage of disease at presentation, patient age and
comorbidities, and the quality of operative management [5, 20, 21]. Deal management should include multidisciplinary consultation regarding NAC, a procedure
that respects oncological principles, optimized perioperative care and the availability of adequate institutional
resources [22]. Disease factors mainly drive survival
outcomes for bladder cancer. The adverse impact of
advanced pT stage and nodal status has been shown, and
long-term survival is dismal when bladder cancer invades
the pelvic sidewall or adjacent structures [3, 4, 12, 23,

0.004

24]. Nodal involvement had a clear negative prognostic
impact independent of pT stage [24].
While disease and patient characteristics are less controllable, disease management and perioperative care are
“modifiable” and should be optimized. It has been previously shown that independent of patient and disease
characteristics, high-quality surgical care is associated
with RFS, DSS and OS [22]. In the current study, more
patients in the OCD received higher quality of care when
compared to LAD (90% vs. 83%), which is attributed
primarily to the pathologic criteria that include positive
soft tissue surgical margins (Table 1). The improvement
in surgical care provided for patients with time corresponds to increased trends of utilization of NAC and is
in agreement with data from National Medicare, which
shows a 37% decline in mortality [22, 25]. Our findings
confirm that quality of surgical care is mandatory to
optimize OS for all patients, irrespective of their disease
status. Among patients with OCD, those who received a
higher quality of surgical care demonstrated better OS
at 5 years (70% vs. 55%, p = 0.03). Among patients with
LAD, disease control benefit (in terms of RFS and DSS)
has been additionally demonstrated. This reflects that a
quality surgery that involves thorough lymphadenectomy
is worthwhile and can provide recurrence-free and disease-free survival benefit even in patients with the locally
advanced and micrometastatic disease. However, controversies do exist with respect to the required extent of
lymphadenectomy and the number of nodes that should
be retrieved. It has been concluded that bilateral and
meticulous lymphadenectomy up to the common iliac
artery is adequate and that such a dissection would provide a yield of approximately 20 lymph nodes [22]. The
introduction of NAC has been associated with improved
survival in these patients, especially in patients with
complete pathological response [8]. Meticulous surgical
clearance and extended lymph node dissection are crucial for achievement of optimal survival following RARC.

Ahmed et al. Afr J Urol

(2020) 26:22

Other factors that have been shown in this study to
affect survival included female gender, ASA score, intracorporeal diversion and continent diversion. Females
in general have worse outcomes of bladder cancer. The
effects of the diversion technique and type may be related
to patient selection bias, where sicker patients usually
receive conduits that are mostly performed intracorporeally, or may be related to longer operative times associated with intracorporeal diversion.
The present study has its limitations. First, the limitations inherent to retrospective analysis are well recognized. Second, the study includes 24 different institutions
which may vary in their management protocols. Still, our
study reflects real practice patterns and may be used for
better patient counseling. Regarding QCS score, an equal
weight was assigned for each of the parameters used,
which may not reflect their actual importance. Also, the
pathologic criteria of QCS may still be affected by disease
stage, which can affect the assessment of the quality of
surgical care.

5 Conclusion
Disease-related factors remain the main determinant of
survival for bladder cancer. Quality of surgical care can
affect disease control and overall survival in patients with
bladder cancer treated with robot-assisted radical cystectomy. In patients with locally advanced disease, quality
surgical care is mandatory to achieve acceptable cancer
control.
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